The Finlay Vaccine Institute (IFV) registered a clinical trial for one of its vaccine candidates on August 13 in the Cuban Public Registry of Clinical Trials. The trial, named SOBERANA 01, is on phase I and II and the first enrollment of subjects is expected on August 24.
The president of the Finlay Vaccine Institute Vicente Vérez said that Cuba is the first country in the underdeveloped world to reach this point. "If you look at the other 29 vaccines in clinical trials, it belongs to rich countries, mainly five rich countries, so getting to this point is a reason of proud," the scientist added.
On the other hand Dagmar García, Research Director at IFV said that Cuba´s vaccine candidate is the number 30 in the world to be approved by its national regulatory entity to advanced to the clinical trials.
According to the Cuban Public Registry of Clinical Trials, these phases include "randomized, controlled, adaptive, double-blind, and multicenter study to evaluate the safety, reactogenicity, and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule."
Cuban vaccine candidate against #COVID-19 will start clinical trials.
Despite cruel blockade that US intensifies every day, the very high quality of our prestigious science, the talent of our scientists and a political will that knows no limits prevails.#CubaSalvaVidas ���� https://t.co/3kn2Yp0DDH
During phase I the vaccine candidate FINLAY-FR-1 is expected to be safe, admitting no more than 5% of individuals with serious adverse events while during phase II The proportion of subjects with an immune response is expected to be at least 50% higher than the control group.
The vaccine candidate FINLAY-FR-1 will be administered to subjects aged between 19-59 and individuals between 60 to 80 years old as well as women of childbearing potential using safe contraceptive methods during the study.
According to the information published in the Cuban Public Registry of Clinical Trials, the two first clinical sites to participate in the study are located in Havana.
The clinical trial is expected to be completed on January 11, 2021, and the first data will be published on February 15, 2021.